3T is an immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations. By leveraging the power of the immune system to recognize, target, and destroy cancer cells, 3T's technology is advancing the development of next-generation therapies that have the potential to be safer, more effective, and even curative for difficult-to-treat cancers.